The AI Trade Takes a Breather to End the Week
The chips are down—a bit.
investopedia.com
NGNE(NGNE)
NGNE
Next earnings: Aug 10, 2026
Signal
Bearish Setup2↓
PRICE
Prev Close
31.27
Open
29.84
Day Range29.63 – 31.04
29.63
31.04
52W Range14.65 – 37.27
14.65
37.27
67% of range
VOLUME & SIZE
Avg Volume
181.8K
FUNDAMENTALS
P/E Ratio
-6.5x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Performance
1D↓
-4.64%5D
-2.13%1M
+24.25%3M↑
+71.58%6M
+30.96%YTD
+44.76%1Y
+53.95%Best: 3M (+71.58%)Worst: 1D (-4.64%)
Quick Read
Trend—Insufficient MA data
Momentum
BEARISH
revenue -100% YoY · thin 0% gross marginValuation
FAIR
P/E not availableHealth
MODERATE
CR 13.1 · FCF negativeLean Bearish
Key MetricsTTM
Market Cap$471.21M
Revenue TTM$0.00
Net Income TTM-$98.64M
Free Cash Flow-$82.61M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-37.9%
Return on Assets-37.5%
Debt / Equity0.04
Current Ratio13.08
EPS TTM$-4.42
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
3 strong3 concern
50/100Liquidity
13.08Strong
Leverage
0.04Strong
Coverage
-36919.0xConcern
ROE
-37.9%Concern
ROIC
-44.8%Concern
Cash
$104MStrong
ANALYST COVERAGE6 analysts
BUY
▲ +131.4%upside to target
Stock Health
Composite Score
3 of 5 signals bullish
7/10
Technicals
●
✗RSI RangeRSI 50 — Bearish momentum
Volume
●
✓Volume FlowAccumulation — institutional buying
Fundamentals
●
✗Last EarningsMissed estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 13.08 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 31, 2026
In 107 days
FinancialsFull statements →
Technicals
Technical SetupBULLISH
Technicals →Trend
▲ UptrendDeath Cross · 50D trails 200D by 7.2%
+50.9% vs SMA 50 · +40.1% vs SMA 200
Momentum
RSI49.6Neutral territory
MACD+0.81Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$37.27+25.0%
Current
$29.82
EMA 200
$21.18-29.0%
EMA 50
$20.73-30.5%
52W Low
$14.65-50.9%
52-Week RangeMid-range
$14.6567th %ile$37.27
Squeeze SetupVolume-based
Moderate Squeeze SetupAccumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
20-Day Money Flow
Acc days:2
Dist days:3
Edge:+1 dist
Volume Context
Avg Vol (50D)157K
Recent Vol (5D)
113K-28%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 7 analysts
Analyst revisions:EPS↑ Revised Up
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $0 | — | -$4.32 | — | ±7% | High5 |
FY2026(current) | $462500 $462500–$462500 | — | -$5.44 | — | ±29% | High7 |
FY2027 | $0 | — | -$5.38 | — | ±16% | Moderate4 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryNGNE
Last 8Q
+3.8%avg beat
Beat 5 of 8 quartersMissed 3↓ Estimates falling-7%
Q3'24
+2%
Q4'24
+5%
Q1'25
-3%
Q2'25
+9%
Q3'25
+21%
Q4'25
+10%
Q1'26
-7%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightInsider Activity
SEC Filings →0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $300K sold · 30d window
Cvijic Christine Mi…Dir
$144K
May 6
SELL
Cvijic Christine Mi…Dir
$156K
May 6
SELL
Cvijic Christine Mi…President and …
$55K
Mar 26
SELL
Mcminn RachelCEO
$74K
Mar 26
SELL
Jordan JulieChief Medical …
$18K
Mar 26
SELL
Cobb StuartChief Scientif…
$81K
Mar 13
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
BlackRock, Inc.
1.0M▲2
JENNISON ASSOCIATES LLC
528K▼3
UBS Group AG
186K▲4
BLAIR WILLIAM & CO/IL
168K▲5
DEUTSCHE BANK AG\
106K▲6
NORTHERN TRUST CORP
98K▲7
VANGUARD FIDUCIARY TRUST CO
70K▲8
JPMORGAN CHASE & CO
65K▲News & Activity
NGNE News
20 articles · 4h ago
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth
prnewswire.com
$60B AI chip darling Cerebras almost died early on, burning $8M a month
techcrunch.com
Tripadvisor: Why I'm Underwriting Tail Risk At $7.00 To Harvest 21% Annualized Yield
seekingalpha.com
Macy's: Berkshire's Thumbs-Up Comes Amid Record-Low Consumer Sentiment
seekingalpha.com
IHE: Healthcare Dashboard For May
seekingalpha.com
Coloplast: Went 'BUY' A Bit Early
seekingalpha.com
CoreWeave: Left Behind In AI Rally - Still A Strong Buy
seekingalpha.com
Seeking Safer +6% Yields
seekingalpha.com
New Phunware CEO unveils hospitality tech 2.0 – ICYMI
proactiveinvestors.com
What we learned about Microsoft in the OpenAI trial, and is Seattle squandering its edge?
geekwire.com
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
seekingalpha.com
Snail returns to profitability in Q1 as revenue surges - ICYMI
proactiveinvestors.com
kneat.com Q1 Earnings Call Highlights
marketbeat.com
Neo Performance Materials Q1 Earnings Call Highlights
marketbeat.com
Northland Power Q1 Earnings Call Highlights
marketbeat.com
Terreno Realty Corporation: This Coastal Industrial REIT Is A Buy
seekingalpha.com
Users turn to jailbreaking their older Kindles as Amazon ends support
techcrunch.com
Why Investors Need to Take Advantage of These 2 Retail and Wholesale Stocks Now
zacks.com
Value, Quality, Momentum, And Lower Volatility In One Emerging Markets Fund
247wallst.com
About
neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. the company was formerly known as aquinox pharmaceuticals, inc. and changed its name to neoleukin therapeutics, inc. in august 2019. neoleukin therapeutics, inc. was founded in 2003 and is headquartered in seattle, washington.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Website
Christine Mikail CvijicPresident, CFO & Director
Andrew E. Mulberg FAAPSenior Vice President of Regulatory Affairs, Quality Assurance & Quality Control
Arvind SreedharanSenior Vice President of Business Operations
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
NGNE◀ | $29.82 | -4.64% | $471M | — | -10000.0% | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.21% | — | 50.3 | +340421.2% | -4085.6% | 1500 |